Skip to main content
Androgenic AlopeciaHair lossAestheticDigital healthSkinLooksmaxxingDevice

What this study is

This single-center, prospective, randomized, placebo-controlled interventional study will evaluate the safety and efficacy of KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap, alone and in combination, for the treatment of female androgenic alopecia. Forty female subjects aged 35 to 55 with clinically diagnosed androgenic alopecia will be randomized into four treatment arms and followed for 24 weeks. The primary objective is to determine whether combination therapy produces greater improvement in hair growth from baseline to 6 months compared with solution alone, device alone, or placebo. Secondary outcomes include changes in hair density, hair fiber diameter, interfollicular distance, terminal-to-vellus hair ratio, patient satisfaction, and safety/tolerability.

What's being tested

  • Scalp Stimulating Serum

    Intervention · OTHER

    Participants assigned to receive the active scalp-stimulating serum will apply one full dropper directly to the scalp once daily and massage it in gently. The product should not be rinsed off. In the combination treatment arm, the serum will be applied immediately before use of the Revian Red Cap.

  • Red Light Hair Growth Cap

    Intervention · DEVICE

    Participants assigned to use the Revian Red Cap will use the device once daily for 10 minutes at a convenient time. The device should be used indoors or in a cool, dry area and only on dry or towel-dried hair. Study staff will assist with unboxing, app registration, and device training at the baseline visit. Device use will be logged through the Revian app.

  • Placebo scalp-stimulating serum

    Intervention · OTHER

    Participants assigned to receive placebo serum will apply one full dropper directly to the scalp once daily and massage it in gently. The placebo product should not be rinsed off. The placebo serum will be identical in appearance and packaging to the active serum and labeled with coded identifiers to maintain blinding.

Study details

Official title
Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy: A Randomized, Placebo Controlled Study
Sponsor
K. Kay Durairaj, MD, FACS, A Medical Corporation
Conditions
Androgenic Alopecia · Female Pattern Hair Loss · Hair Loss
Enrolling
40 people
Starts
2026-03-17
Est. completion
2027-01-01
Design
Double-blind, randomized, factorial
Record
View on ClinicalTrials.gov ↗